文献速递支持与姑息治疗

改善晚期癌症患者生活质量:靶向转移性骨痛

Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain.
PubMed 文献 · Eur J Cancer · 2016-12-14

本综述探讨如何优化转移性骨痛管理以减轻患者负担。癌痛常被低报和低治疗,现有非阿片和阿片类镇痛药、放疗、手术、放射性药物及骨靶向药物(双膦酸盐和地诺单抗)等多种选择。推荐所有转移性骨病患者起始骨靶向药物治疗,因其可延迟骨相关事件和骨痛发生。

要点

  • 癌痛常被低报和低治疗,尽管有多种治疗选择。
  • 放疗是转移性骨痛患者当前的标准治疗,常与阿片类镇痛药联用。
  • 推荐所有转移性骨病患者起始骨靶向药物治疗,以延迟骨相关事件和骨痛发生。

核心结论

  • 适当的抗肿瘤治疗联合早期起始骨靶向药物和充分镇痛在癌症疼痛管理整体方法中起关键作用,可能最小化转移性骨痛的衰弱效应。

研究设计与样本

  • 本综述考虑如何优化转移性骨痛的管理,以限制其对患者造成的显著负担。

主要发现

  • 转移性骨病常伴随骨骼并发症,可导致疼痛、功能受损、生活质量下降及生存期缩短。
  • 癌痛常被低报和低治疗,尽管有许多治疗选择可用。
  • 非阿片和阿片类镇痛药可使用;后者通常与放疗联合给药,放疗构成转移性骨痛患者当前的标准治疗。
  • 手术适用于某些复杂转移性骨病病例,放射性药物等其他选择可能提供额外缓解。
  • 骨靶向药物(双膦酸盐和地诺单抗)可进一步减轻疼痛;推荐所有转移性骨病患者起始骨靶向药物治疗,因为这些药物不仅延迟骨相关事件的发生,也延迟骨痛的发生。

临床怎么用

  • 适当的抗肿瘤治疗联合早期起始骨靶向药物和充分镇痛是癌症疼痛管理整体方法的关键组成部分。
  • 优化治疗依赖于医生充分理解各种药物可能实现的互补获益及其局限性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metastatic bone disease in patients with advanced cancer is frequently associated with skeletal complications. These can be debilitating, causing pain, impaired functioning and decreased quality of life, as well as reduced survival. This review considers how the management of metastatic bone pain might be optimised, to limit the considerable burden it can impose on affected patients. Cancer-related pain is notoriously under-reported and under-treated, despite the availability of many therapeutic options. Non-opioid and opioid analgesics can be used; the latter are typically administered with radiotherapy, which forms the current standard of care for patients with metastatic bone pain. Surgery is appropriate for certain complicated cases of metastatic bone disease, and other options such as radiopharmaceuticals may provide additional relief. Treatments collectively referred to as bone-targeted agents (BTAs; bisphosphonates and denosumab) can offer further pain reduction. Initiation of therapy with BTAs is recommended for all patients with metastatic bone disease because these agents delay not only the onset of skeletal-related events but also the onset of bone pain. With evidence also emerging for pain control properties of new anticancer agents, the potential to individualise care for these patients is increased further. Optimisation of care depends on physicians' thorough appreciation of the complementary benefits that might be achieved with the various agents, as well as their limitations. Appropriate anti-tumour treatment combined with early initiation of BTAs and adequate analgesia plays a key role in the holistic approach to cancer pain management and may minimise the debilitating effects of metastatic bone pain.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. von Moos R, Costa L, Ripamonti CI, et al. Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. Eur J Cancer. 2016. PMID: 27984770. doi:10.1016/j.ejca.2016.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。